Natixis Advisors LLC Reduces Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Natixis Advisors LLC lessened its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 515,428 shares of the medical equipment provider’s stock after selling 23,205 shares during the period. Natixis Advisors LLC owned 0.15% of Intuitive Surgical worth $229,288,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Equitable Trust Co. lifted its position in shares of Intuitive Surgical by 11.5% during the 2nd quarter. Equitable Trust Co. now owns 3,680 shares of the medical equipment provider’s stock valued at $1,637,000 after buying an additional 381 shares during the last quarter. GraniteShares Advisors LLC lifted its holdings in Intuitive Surgical by 3.1% during the 2nd quarter. GraniteShares Advisors LLC now owns 3,644 shares of the medical equipment provider’s stock worth $1,621,000 after purchasing an additional 108 shares in the last quarter. Fielder Capital Group LLC lifted its holdings in Intuitive Surgical by 1.7% during the 2nd quarter. Fielder Capital Group LLC now owns 2,544 shares of the medical equipment provider’s stock worth $1,132,000 after purchasing an additional 43 shares in the last quarter. Drive Wealth Management LLC lifted its holdings in Intuitive Surgical by 2.9% during the 2nd quarter. Drive Wealth Management LLC now owns 1,257 shares of the medical equipment provider’s stock worth $559,000 after purchasing an additional 36 shares in the last quarter. Finally, Tandem Investment Advisors Inc. lifted its holdings in Intuitive Surgical by 1.1% during the 2nd quarter. Tandem Investment Advisors Inc. now owns 11,905 shares of the medical equipment provider’s stock worth $5,296,000 after purchasing an additional 124 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Trading Up 1.1 %

NASDAQ ISRG traded up $5.46 on Friday, hitting $492.63. The company’s stock had a trading volume of 1,097,792 shares, compared to its average volume of 1,235,701. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $493.97. The company’s 50-day simple moving average is $454.69 and its 200 day simple moving average is $414.70. The firm has a market cap of $175.06 billion, a P/E ratio of 88.92, a PEG ratio of 5.43 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.18 EPS. On average, research analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ISRG has been the topic of a number of recent research reports. Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $380.00 to $510.00 in a report on Friday, August 2nd. BTIG Research upped their target price on Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a research note on Wednesday. Evercore ISI decreased their target price on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a research note on Friday, July 19th. Morgan Stanley upped their target price on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Finally, Piper Sandler upped their target price on Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $446.45.

Insider Activity

In other news, EVP Robert Desantis sold 396 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $486.88, for a total value of $192,804.48. Following the completion of the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,680,761.28. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, SVP Henry L. Charlton sold 40,243 shares of Intuitive Surgical stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the completion of the transaction, the senior vice president now owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Robert Desantis sold 396 shares of Intuitive Surgical stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $486.88, for a total value of $192,804.48. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at approximately $2,680,761.28. The disclosure for this sale can be found here. Insiders sold a total of 55,552 shares of company stock worth $26,281,657 in the last quarter. 0.90% of the stock is owned by company insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.